Eczema is a chronic skin condition that shares similarities with autoimmune skin conditions, but it’s not an autoimmune ...

In an investor update on Tuesday, Amgen Inc (NASDAQ:AMGN) released data from Phase 3 trials of rocatinlimab and Uplizna ...

In a statement, the association emphasized that the campaign aims to raise awareness about the proper management of atopic ...

Ebglyss is a new biologic treatment for moderate-to-severe eczema that isn’t controlled with topical therapies. The ...

ZORYVE demonstrated consistent efficacy in disease clearance and reduction in itch for individuals with atopic dermatitis (AD) regardless of ...

Dermatitis, or atopic eczema, is among the most prevalent and least recognized skin diseases. Dr. José Alberto Torres, an ...

Galderma today announced that it will present new data from the ARCADIA and OLYMPIA clinical trial programs investigating ...

Kyowa Kirin Co., Ltd. (Kyowa Kirin) (TSE:4151) (President and CEO: Masashi Miyamoto) announced top-line results of the Phase 3 ROCKET HORIZON trial of rocatinlimab, an investigational therapy ...

The US food and Drug Administration has approved lebrikizumab for treatment of atopic dermatitis in adults and children ages ...

The FDA has approved lebrikizumab (Ebglyss; Eli Lilly) as a new first-line biologic treatment for patients aged 12 and older ...

The Food and Drug Administration (FDA) has approved Ebglyss™ (lebrikizumab-lbkz) for the treatment of adult and pediatric ...

Atopic dermatitis (one type of eczema), in particular, may exist on a spectrum with autoimmune disease, and having it may increase your risk of autoimmune conditions. Evgeniia Gordeeva / Getty ...